BAXTER INVESTS $20 MIL. IN TRANSPLANT TECHNOLOGY PARTNERSHIP WITH DNX
This article was originally published in The Gray Sheet
Executive Summary
BAXTER INVESTS $20 MIL. IN TRANSPLANT TECHNOLOGY PARTNERSHIP WITH DNX, according to the companies. The new entity, Nextran, will seek to develop and commercialize technologies "to improve the success and increase the availability of organ transplantation." Under the terms of the agreement, Baxter will own 70% of Nextran, and Princeton, New Jersey-based DNX will hold 30% of the firm. Nextran will operate as an affiliate of Baxter.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.